MX382608B - Tratamiento del prurito urémico. - Google Patents
Tratamiento del prurito urémico.Info
- Publication number
- MX382608B MX382608B MX2018011379A MX2018011379A MX382608B MX 382608 B MX382608 B MX 382608B MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 382608 B MX382608 B MX 382608B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- uremic pruritus
- pruritus
- uremic
- patient
- Prior art date
Links
- 206010060875 Uraemic pruritus Diseases 0.000 title abstract 2
- 230000001139 anti-pruritic effect Effects 0.000 abstract 1
- 239000003908 antipruritic agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311134P | 2016-03-21 | 2016-03-21 | |
| US201662412584P | 2016-10-25 | 2016-10-25 | |
| PCT/US2017/023398 WO2017165409A1 (en) | 2016-03-21 | 2017-03-21 | Treatment of uremic pruritus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018011379A MX2018011379A (es) | 2019-06-13 |
| MX382608B true MX382608B (es) | 2025-03-13 |
Family
ID=59899743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011379A MX382608B (es) | 2016-03-21 | 2017-03-21 | Tratamiento del prurito urémico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180008592A1 (enExample) |
| EP (1) | EP3432871B1 (enExample) |
| JP (2) | JP2019509309A (enExample) |
| KR (1) | KR20180120756A (enExample) |
| CN (1) | CN109310656A (enExample) |
| AU (1) | AU2017238051B9 (enExample) |
| BR (1) | BR112018069174A2 (enExample) |
| CA (1) | CA3017374A1 (enExample) |
| ES (1) | ES2970294T3 (enExample) |
| MX (1) | MX382608B (enExample) |
| WO (1) | WO2017165409A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019301134A1 (en) * | 2018-07-11 | 2021-01-21 | Trevi Therapeutics, Inc. | Treatment of the pruritic symptoms of liver disease |
| CN118512451A (zh) | 2018-07-23 | 2024-08-20 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| IL294601A (en) | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administration of nalbuphine |
| WO2021222886A1 (en) * | 2020-05-01 | 2021-11-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods to treat polycystic kidney disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1535687A (zh) * | 1996-11-25 | 2004-10-13 | ������������ʽ���� | 止痒药物 |
| WO2009047562A1 (en) * | 2007-10-08 | 2009-04-16 | Serentis Limited | Methods and compositions for the treatment of pruritus |
| US8686040B2 (en) * | 2008-03-31 | 2014-04-01 | Rdd Pharma Ltd. | Method for treating anal pruritis and other perianal disorders |
| US8637538B1 (en) * | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| JP2016506398A (ja) * | 2012-12-14 | 2016-03-03 | トレビ セラピューティクス インコーポレイテッド | そう痒の処置法 |
| US8987289B2 (en) * | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| WO2015192071A1 (en) * | 2014-06-13 | 2015-12-17 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
-
2017
- 2017-03-21 CA CA3017374A patent/CA3017374A1/en active Pending
- 2017-03-21 CN CN201780025588.8A patent/CN109310656A/zh active Pending
- 2017-03-21 WO PCT/US2017/023398 patent/WO2017165409A1/en not_active Ceased
- 2017-03-21 BR BR112018069174A patent/BR112018069174A2/pt not_active IP Right Cessation
- 2017-03-21 ES ES17770981T patent/ES2970294T3/es active Active
- 2017-03-21 US US15/465,158 patent/US20180008592A1/en not_active Abandoned
- 2017-03-21 MX MX2018011379A patent/MX382608B/es unknown
- 2017-03-21 EP EP17770981.3A patent/EP3432871B1/en active Active
- 2017-03-21 KR KR1020187029246A patent/KR20180120756A/ko not_active Ceased
- 2017-03-21 JP JP2018549563A patent/JP2019509309A/ja active Pending
- 2017-03-21 AU AU2017238051A patent/AU2017238051B9/en active Active
-
2022
- 2022-03-17 JP JP2022042056A patent/JP2022081640A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018011379A (es) | 2019-06-13 |
| US20180008592A1 (en) | 2018-01-11 |
| EP3432871A1 (en) | 2019-01-30 |
| EP3432871B1 (en) | 2023-11-15 |
| AU2017238051B9 (en) | 2022-11-03 |
| CN109310656A (zh) | 2019-02-05 |
| KR20180120756A (ko) | 2018-11-06 |
| AU2017238051B2 (en) | 2022-10-06 |
| JP2019509309A (ja) | 2019-04-04 |
| EP3432871A4 (en) | 2019-10-30 |
| CA3017374A1 (en) | 2017-09-28 |
| BR112018069174A2 (pt) | 2019-01-29 |
| ES2970294T3 (es) | 2024-05-27 |
| WO2017165409A1 (en) | 2017-09-28 |
| AU2017238051A1 (en) | 2018-10-04 |
| JP2022081640A (ja) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502075B1 (en) | Treatment of cataplexy | |
| MX384240B (es) | Bacterias probioticas recombinantes. | |
| EA201791208A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| MY194341A (en) | Method of treating a brain tumor | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| EA201791110A1 (ru) | Сублингвальное введение рилузола | |
| EA201790442A1 (ru) | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae | |
| PH12016502150A1 (en) | Method for treating renal cell carcimona | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| JOP20190056B1 (ar) | مركبات للاستخدام في علاج القصور الكلوي الحاد | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| MX2017006019A (es) | Apilimod para uso en el tratamiento de melanoma. | |
| MX2018011379A (es) | Tratamiento del prurito uremico. | |
| MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
| MX2017007245A (es) | Metodos de tratamiento de la fibrosis. | |
| MX376191B (es) | Composicion hiperosmolar de acido hialuronico. | |
| EP3549582A3 (en) | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases | |
| MX2016002307A (es) | Tratamiento para el cancer. | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| CY1125266T1 (el) | To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων | |
| MX2017013669A (es) | Composiciones para el tramiento del cancer. |